Smith & Nephew (LON:SN) Stock Rating Reaffirmed by Citigroup

Citigroup reiterated their buy rating on shares of Smith & Nephew (LON:SN – Get Rating) in a report published on Tuesday morning, Marketbeat.com reports.

A number of other brokerages have also issued reports on SN. Liberum Capital upgraded shares of Smith & Nephew to a buy rating and upped their target price for the stock from GBX 1,120 ($13.65) to GBX 1,410 ($17.18) in a research report on Wednesday, March 1st. Barclays lowered their target price on shares of Smith & Nephew from GBX 1,500 ($18.28) to GBX 1,480 ($18.04) and set an overweight rating for the company in a research note on Wednesday, February 22nd. Finally, Berenberg Bank reaffirmed a buy rating and issued a GBX 1,400 ($17.06) target price on shares of Smith & Nephew in a research note on Wednesday, March 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Smith & Nephew currently has an average rating of Moderate Buy and an average price target of GBX 1,405.50 ($17.13).

Smith & Nephew Price Performance

Shares of SN stock opened at GBX 1,197.50 ($14.59) on Tuesday. Smith & Nephew has a 1 year low of GBX 959.20 ($11.69) and a 1 year high of GBX 1,338.50 ($16.31). The firm’s 50 day moving average is GBX 1,165.69 and its 200-day moving average is GBX 1,093.50. The firm has a market capitalization of £10.46 billion, a price-to-earnings ratio of 5,630.95, a PEG ratio of 1.31 and a beta of 0.35. The company has a current ratio of 2.25, a quick ratio of 0.84 and a debt-to-equity ratio of 54.61.

Smith & Nephew Increases Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, May 17th. Stockholders of record on Thursday, March 30th will be given a dividend of $0.23 per share. This is an increase from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date is Thursday, March 30th. This represents a dividend yield of 1.65%. Smith & Nephew’s dividend payout ratio is currently 15,238.10%.

About Smith & Nephew

(Get Rating)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.